Clinical Trial Update: Phase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC [Phase 2]

View source ↗

Summary

Phase II clinical study evaluating Befotertinib in patients with EGFR non-classical mutant non-small cell lung cancer is underway. The trial is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Befotertinib

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: NSCLC (Non-small Cell Lung Cancer) | Phase 2 | Status: RECRUITING